UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 | --- | --- | |----------------------------------------------------------------------------|------------------------------- ...

Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers • Abstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting • Cash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, CA, Aug. 13, 2024 – Bolt ...

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers Abstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Cash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel i ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bolt To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Bolt between February 5, 2021 and May 14, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BOLT. NEW YORK, Aug. 7, ...

NEW YORK, Aug. 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), of the important September 3, 2024 lead plaintiff deadline. SO WHAT: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

Follow us for updates on LinkedIn, on X, or on Facebook. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) BDC-1001 was less eff ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), of the important September 3, 2024 lead plaintiff deadline. WHAT TO DO NEXT: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class ac ...

If you are a shareholder who suffered a loss, click here to participate. LOS ANGELES, July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. CONTACT: The Schall Law Firm Brian Schall, Esq. ...

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The complaint alleges that on May 14, 2024, Bolt issued a press release announcing that the Company would cease further development of BDC-1001 and focus resources on BDC-3042 and BDC-4182 upon determining that BDC-1001 failed to meet its pre-defined success criteria, that the Company's Chief Executive Officer Randall C. Schatzman and Chief Medical Officer Edith Perez would be moved into advisory roles ...

SO WHAT: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) BDC-1001, Bolt's immune-stimulating antibody conjugate ("ISAC") designed to target a tumor antigen known as human epidermal growth factor receptor 2 ("HER2") that is often found in cance ...